Verve Therapeutics, Inc. (VERV) Financial Analysis & Valuation | Quarter Chart
Verve Therapeutics, Inc. (VERV)
VERVPrice: $11.13
Fair Value: 🔒
🔒score
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also ... more
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines ... more
Description
Shares
| Market Cap | $994.04M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Sekar Kathiresan |
| IPO Date | 2021-06-17 | CAGR | — |
| Employees | 274 | Website | www.vervetx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
VERV chart loading...
Fundamentals
Technicals
| Enterprise Value | $377.88M | P/E Ratio | -5.27 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 16.67 | P/B Ratio | 2.09 |
| P/CF Ratio | -6.94 | P/FCF Ratio | -6.76 |
| EPS | $-2.11 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 271.44% | Gross Margin | 1% |
| Operating Margin | -3.5% | Profit Margin | -3.04% |
| ROE | -0.36% | ROA | -0.29% |
| ROCE | -0.37% | Current Ratio | 9.84 |
| Quick Ratio | 9.84 | Cash Ratio | 1.86 |
| Debt/Equity | 0.14 | Interest Coverage | — |
| Altman Z Score | 2.35 | Piotroski Score | 2 |